<DOC>
	<DOC>NCT00786812</DOC>
	<brief_summary>Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the [CAMN107A2109] study</brief_summary>
	<brief_title>Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. patients currrently participating in Novartis study CAMN107A2109 2. imatinib resistant or intolerant Philadelphia chromosomepositive CML in chronic (CMLCP)accelerated phase (CMLAP) or in blast crisis (CMLBC) 3. males or females ≥18 years of age 4. WHO Performance Status of ≤ 2 5. patients must have the following laboratory values: ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN if considered due to tumor 1. Impaired cardiac function; use of therapeutic coumarin derivatives 2. patients who have undergone a major surgery and have not recovered from side effects of such therapy within 15 days 3. patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control 4. patients who have received chemotherapy ≤ 1 week or who are within 5 halflives of their last dose of chemotherapy 5. ,.patients who have received imatinib or dasatinib at least 3 days prior to beginning of study drug or who have not recovered from side effects of such therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>adult chronic myeloid leukemia</keyword>
	<keyword>imatinib</keyword>
	<keyword>nilotinib</keyword>
</DOC>